In this article, we are going to take a look at where Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX) stands against other high growth low debt stocks to invest in now. The global financial ...

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025. The Dow Jones closed lower by ...

Short interest in Protalix BioTherapeutics Inc (AMEX:PLX) increased during the last reporting period, rising from 650.64K to 979.39K. This put 1.31% of the company's publicly available shares short.

San Jose, Calif., December 13, 2011—Altera Corporation (Nasdaq: ALTR) today announced it has successfully interoperated its 28-nm Stratix® V GX FPGA with PLX® Technology's (Nasdaq: PLXT) ExpressLane™ ...